These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32879028)

  • 1. Pre-exposure HIV prophylaxis (PrEP) among transgender women: 3 years of follow-up in a university hospital in Paris.
    Isernia V; Phung B; Lepretre AM; Azadi B; Rincon G; Zelie J; Le Gac S; Deprez A; Michard F; Yazdanpanah Y; Ghosn J
    Sex Transm Infect; 2021 Sep; 97(6):465-466. PubMed ID: 32879028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlates of nonadherence to key population-led HIV pre-exposure prophylaxis services among Thai men who have sex with men and transgender women.
    Seekaew P; Nguyen E; Sungsing T; Jantarapakde J; Pengnonyang S; Trachunthong D; Mingkwanrungruang P; Sirisakyot W; Phiayura P; Panpet P; Meekrua P; Praweprai N; Suwan F; Sangtong S; Brutrat P; Wongsri T; Nakorn PRN; Mills S; Avery M; Vannakit R; Phanuphak P; Phanuphak N
    BMC Public Health; 2019 Mar; 19(1):328. PubMed ID: 30898095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with long-term HIV pre-exposure prophylaxis engagement and adherence among transgender women in Brazil, Mexico and Peru: results from the ImPrEP study.
    Konda KA; Torres TS; Mariño G; Ramos A; Moreira RI; Leite IC; Cunha M; Jalil EM; Hoagland B; Guanira JV; Benedetti M; Pimenta C; Vermandere H; Bautista-Arredondo S; Vega-Ramirez H; Veloso VG; Caceres CF; Grinsztejn B;
    J Int AIDS Soc; 2022 Oct; 25 Suppl 5(Suppl 5):e25974. PubMed ID: 36225148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acceptability of HIV Pre-Exposure Prophylaxis Among Transgender Women in India: A Qualitative Investigation.
    Chakrapani V; Shunmugam M; Rawat S; Baruah D; Nelson R; Newman PA
    AIDS Patient Care STDS; 2020 Feb; 34(2):92-98. PubMed ID: 31951490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "I wish to remain HIV negative": Pre-exposure prophylaxis adherence and persistence in transgender women and men who have sex with men in coastal Kenya.
    Kimani M; van der Elst EM; Chirro O; Wahome E; Ibrahim F; Mukuria N; de Wit TFR; Graham SM; Operario D; Sanders EJ
    PLoS One; 2021; 16(1):e0244226. PubMed ID: 33465090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Demonstration project of oral TDF-containing PrEP, administered, once-daily orally to men having sex with men (MSM) and transgender women (TGW) in India: Study protocol.
    Sahay S; Bangar S; Chandhiok N
    PLoS One; 2023; 18(6):e0287454. PubMed ID: 37352188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PrEP interest and HIV-1 incidence among MSM and transgender women in coastal Kenya.
    Kimani M; van der Elst EM; Chiro O; Oduor C; Wahome E; Kazungu W; Shally M; Rinke de Wit TF; Graham SM; Operario D; Sanders EJ
    J Int AIDS Soc; 2019 Jun; 22(6):e25323. PubMed ID: 31194291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study.
    Marins LMS; Torres TS; Leite IDC; Moreira RI; Luz PM; Hoagland B; Kallas EG; Madruga JV; Liu AY; Anderson PL; Grinsztejn B; Veloso VG
    PLoS One; 2019; 14(8):e0221281. PubMed ID: 31430318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urine tenofovir testing for real-time PrEP adherence feedback: a qualitative study involving transgender women in Uganda.
    Mujugira A; Karungi B; Mugisha J; Nakyanzi A; Nampewo O; Naddunga F; Kamusiime B; Nsubuga R; Nyanzi KR; Muwonge TR; Wyatt MA; Ware NC; Gandhi M; Haberer JE
    J Int AIDS Soc; 2024 May; 27(5):e26255. PubMed ID: 38695107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Princess PrEP program: the first key population-led model to deliver pre-exposure prophylaxis to key populations by key populations in Thailand.
    Phanuphak N; Sungsing T; Jantarapakde J; Pengnonyang S; Trachunthong D; Mingkwanrungruang P; Sirisakyot W; Phiayura P; Seekaew P; Panpet P; Meekrua P; Praweprai N; Suwan F; Sangtong S; Brutrat P; Wongsri T; Na Nakorn PR; Mills S; Avery M; Vannakit R; Phanuphak P
    Sex Health; 2018 Nov; 15(6):542-555. PubMed ID: 30249317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prepped for PrEP? Acceptability, continuation and adherence among men who have sex with men and transgender women enrolled as part of Vietnam's first pre-exposure prophylaxis program.
    Green KE; Nguyen LH; Phan HTT; Vu BN; Tran MH; Ngo HV; Tieu VTT; Van H; Le TM; Do KQ; Nguyen PA; Ngo TM; Doan AH; Bui DTN; Nguyen TNN; Hang LTX; Tran TT; Luong BQ
    Sex Health; 2021 Mar; 18(1):104-115. PubMed ID: 33653505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the impact of policies recommending PrEP to subpopulations of men and transgender women who have sex with men based on demographic and behavioral risk factors.
    Janes H; Brown MD; Glidden DV; Mayer KH; Buchbinder SP; McMahan VM; Schechter M; Guanira J; Casapia M
    PLoS One; 2019; 14(9):e0222183. PubMed ID: 31536518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
    Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "I felt special!": a qualitative study of peer-delivered HIV self-tests, STI self-sampling kits and PrEP for transgender women in Uganda.
    Mujugira A; Karungi B; Mugisha J; Nakyanzi A; Bagaya M; Kamusiime B; Nalumansi A; Nalukwago GK; Kasiita V; Twesigye CC; Nampewo O; Nsubuga R; Nyanzi KR; Muwonge T; Wyatt MA; Ware NC; Haberer JE
    J Int AIDS Soc; 2023 Dec; 26(12):e26201. PubMed ID: 38147031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying priority groups for pre-exposure prophylaxis among sex workers in Flanders, Belgium: insights into routine HIV and sexually transmitted infection data in community-based clinics.
    Van Mieghem H; Nöstlinger C; Smekens T; De Cannière AS; Keersmaekers K; Scheerder G; De Baetselier I; Vuylsteke B
    Sex Transm Infect; 2024 May; 100(4):236-241. PubMed ID: 38821864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lived experiences with pre-exposure prophylaxis uptake and adherence among transgender women in Thailand: a qualitative study.
    Janamnuaysook R; Guo Y; Yu YJ; Phanuphak N; Kawichai S; MacDonell K; Jupimai T; Rongkavilit C; Wang B
    Sex Health; 2024 Jan; 21():. PubMed ID: 38219741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stopping and restarting PrEP and loss to follow-up among PrEP-taking men who have sex with men and transgender women at risk of HIV-1 participating in a prospective cohort study in Kenya.
    Wahome E; Boyd A; Thiong'o AN; Mohamed K; Oduor T; Gichuru E; Mwambi J; van der Elst E; Graham SM; Prins M; Sanders EJ
    HIV Med; 2022 Aug; 23(7):750-763. PubMed ID: 35088511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low PrEP adherence despite high retention among transgender women in Brazil: the PrEParadas study.
    Jalil EM; Torres TS; Luz PM; Monteiro L; Moreira RI; de Castro CRV; Leite IDC; Cunha M; de Cássia Elias Estrela R; Ramos M; Hoagland B; Wagner Cardoso S; Anderson P; Veloso VG; Wilson E; Grinsztejn B;
    J Int AIDS Soc; 2022 Mar; 25(3):e25896. PubMed ID: 35255199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "It's behaviors, not identity": Attitudes and beliefs related to HIV risk and pre-exposure prophylaxis among transgender women in the Southeastern United States.
    Van Gerwen OT; Austin EL; Camino AF; Odom LV; Muzny CA
    PLoS One; 2022; 17(1):e0262205. PubMed ID: 35085284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy.
    Yager JL; Anderson PL
    Expert Opin Drug Metab Toxicol; 2020 Jun; 16(6):463-474. PubMed ID: 32250177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.